trending Market Intelligence /marketintelligence/en/news-insights/trending/7lyZds-S7E0BWUM-MpOQ4A2 content esgSubNav
In This List

Teva drops patent suit against Mylan over multiple sclerosis drug

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Teva drops patent suit against Mylan over multiple sclerosis drug

Mylan NV said Teva Pharmaceutical Industries Ltd. dismissed a patent infringement lawsuit against Mylan after a U.S. district court accepted Mylan's interpretation of the patents' claims.

Teva brought the lawsuit in the U.S. District Court for the District of Delaware alleging that Mylan's Glatiramer Acetate Injection 40 milligrams/milliliters infringed on two patents of its multiple sclerosis drug Copaxone 40 mg/ml.

The company added that Teva has agreed to withdraw the Irish equivalent to these patents from the proceeding filed in Ireland.

Mylan said Teva's only remaining patent challenges in the U.S. and Ireland against its generic relate to the three-times-a-week dosing regimen, which has already been invalidated at the U.K.'s High Court of Justice, at a U.S. district court and at the U.S. Patent Trial and Appeal Board. Teva is appealing the decisions in these cases.